Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Financing Activities (2016 - 2025)

Neuroone Medical Technologies' Cash from Financing Activities history spans 14 years, with the latest figure at $147823.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 129.02% year-over-year to $147823.0; the TTM value through Dec 2025 reached $8.7 million, up 56.37%, while the annual FY2025 figure was $8.0 million, 10.45% up from the prior year.
  • Cash from Financing Activities reached $147823.0 in Q4 2025 per NMTC's latest filing, up from $66978.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $12.0 million in Q4 2021 to a low of -$509325.0 in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $2.3 million, with a median of $933487.5 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 205677.95% in 2023, then plummeted 142.27% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $12.0 million in 2021, then crashed by 100.13% to -$15713.0 in 2022, then soared by 7768.9% to $1.2 million in 2023, then plummeted by 142.27% to -$509325.0 in 2024, then skyrocketed by 129.02% to $147823.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Cash from Financing Activities are $147823.0 (Q4 2025), $66978.0 (Q3 2025), and $8.2 million (Q2 2025).